Precision Biopsy said today it won an investigational device exemption from the FDA to expand the trial of its ClariCore biopsy system, now looking to enroll prostate cancer patients in the newly cleared Transrectal Ultrasound and MR/Fusion arms of the study. The ClariCore system is designed for the spectral analysis of tissue samples during biopsies to “rapidly […]
Precision Biopsy asks FDA to OK new ClariCore trial
Precision Biopsy said today it submitted an application to the FDA seeking a go-ahead to expand the trial of its ClariCore prostate biopsy system into a new Transrectal Ultrasound and MR/Fusion arm. The ClariCore system is designed for the spectral analysis of tissue samples during biopsies to “rapidly classify” tissue as normal or suspicious using an […]
Precision Biopsy pulls in $33.6m
Precision Biopsy said today it raised $33.6 million in a new round of equity financing to support its ClariCore biopsy platform designed to provide prostate tissue classification during biopsy procedures. Woodford Investment Management led the round, according to Aurora, Colo.-based Precision Biopsy, with investments from its parent company Allied Minds. The ClariCore system is designed […]
Eye treatment company Avedro lands $25 million | Funding Roundup
Avedro Inc. landed $25 million in a series C financing round, company officials announced yesterday.
The Waltham, Mass.-based company will use the funds to expand its commercial operations overseas.
Avedro, a private company, also plans to pursue U.S. Food and Drug Administration clearance for its Vedera cornea flattening treatment, designed to treat near-sightedness, and its KXL corneal cross-linking system.
The KXL system won CE Mark approval in the European Union in November 2010.
